An observational study in Cardiogenic Shock Post Myocardial Infarction, sponsored by University Hospital of Cologne. Recruiting at 3 sites in Germany. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University Hospital of Cologne · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 9th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 35th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:
Leipzig Heart Science gGmbH · Sites in Germany
Ages 18–80
4TEEN4 Pharmaceuticals GmbH · Sites in Germany, Armenia, Belgium and 6 more countries
Ages 18–80
Abiomed Inc. · Sites in Germany, Italy, Switzerland
Ages 18+
University Heart Center Freiburg - Bad Krozingen · Sites in Germany
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 115 is below the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 60 across the 22 interventional studies, 138 across the 14 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
University Hospital of Cologne is the lead sponsor of 42 studies on the registry; 15 are open to participants now.
University Hospital of Cologne has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Cardiogenic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT06308055Abiomed Inc.Abiomed Impella RT-DAQ - Observational Study | 2027-06-30 |
| NCT07515508University Heart Center Freiburg - Bad KrozingenMultimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE | 2027-07-31 |
| NCT07687017Leipzig Heart Science gGmbHCRP Apheresis in Infarct-Related Cardiogenic Shock | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to evaluate whether a structured and time-optimized escalation strategy from a transfemoral microaxial flow-pump (Impella CP™) to the Impella 5.5™ microaxial flow-pump is associated with improved clinical outcomes and fewer adverse events in patients with cardiogenic shock due to acute myocardial infarction
By examining best-practice MCS management and the role of early escalation to Impella 5.5™ in clinical routine care for high-risk patients with deteriorating shock, the study seeks to investigate current treatment strategies that ensure the most appropriate device selection and support intensity at the earliest clinically meaningful time point. This observational approach aims to advance the optimal management of ACS-CS while addressing the complications reported in the DanGer Shock trial.
Patients with ACS-CS (STEMI or NSTEMI) who undergo Impella CP™-supported revascularisation of the culprit lesion and are considered for escalation to Impella 5.5 at the discretion of the treating investigator will be assessed for eligibility to participate in this observational study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following additional parameters must be met at the time of initial revascularisation procedure:
Need for escalation to Impella 5.5 at the discretion of the treating physician and the following criteria are fulfilled:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rapid escalation to Impella 5.5
Device: Escalation to more capable microaxial flow-pump (Impella 5.5)
Rapid escalation from Impella CP to Impella 5.5 within 24 hours post revascularization
Vasoactive Hemodynamic Score (VHS) < 5
Vasoactive Hemodynamic Score = Hemodynamic Score (HS) x Vasoactive-Inotropic Score (VIS) Higher VHS indicates more severe hemodynamic compromise relative to degree of pharmacological circulatory support. Range: Minimum 1, Maximum 110 Hemodynamic Score: HS = Points are allocated for measured heart rate, mean arterial blood pressure and arterial lactate (minimum 1, maximum 11) Vasoactive-Inotropic Score: Points are allocated for every 10 increment according to the following formula: Dopamine dose (μg/kg/min) + Dobutamine dose (μg/kg/min) + 100 x Epinephrine dose (μg/kg/min) + 10 x Milrinone (μg/kg/min) + 100 x Norepinephrine dose (μg/kg/min) + 50 x Levosimendan dose (μg/kg/min)
Time frame: 48 hours post revascularization
All-cause mortality
Time frame: In-hospital or 30 days post revascularization (whatever comes first)
All-cause mortality
Time frame: 180 days post revascularization
Cardiac output
measured by pulmonary artery catheter (PAC) \[l/min\]
Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularization.
Vasoactive-Inotropic Score (VIS)
Vasoactive-Inotropic Score (VIS): A composite measure of vasoactive and inotropic medication support. Scores range from 0 to no fixed maximum, with higher scores indicating greater vasoactive/inotropic support requirements and therefore a worse clinical status and prognosis. VIS=dopamine + dobutamine + 100×epinephrine + 10×milrinone + 10,000×vasopressin + 100×norepinephrine (all doses in μg/kg/min except vasopressin in U/kg/min)
Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularization.
Lactate
Arterial lactate measured by blood gas analysis \[mmol/l\]
Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularisation
Perfusion
Enhanced perfusion of the limb used for Impella CP™ access by comparing NIRS measurements \[%\]
Time frame: At time of enrolment and 48 hours post revascularization.
Major Bleeding
Either according to BARC classification (BARC ≥ IIIa) or GUSTO classification (at least moderate bleeding)
Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) until the first documented bleeding event.
Ischemia of the extremities
Peripheral vascular ischemia (femoral and axillary) with indication to percutaneous intervention or surgical repair
Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timepoint of intervention/surgery assessed up to 30 days.
Haemolysis
Prevalence of clinically relevant haemolysis according to SHARC definitions
Time frame: At time of enrolment, 48 hours as well as 72 hours post revascularization.
Cerebral events
Cerebral ischemia or cerebral bleeding assessed via standard-of-care neurological assessment and/or imaging
Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) assessed up to 30 days.
Acute kidney injury (AKI)
Acute kidney injury (AKIN level 2 or greater) and/or need for renal replacement therapy (RRT)
Time frame: Every event during the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first), assessed at the timepoint of occurence up to 30 days.
Sepsis with positive blood culture
Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timpoint of first positive blood culture up to 30 days.
Access site infection
Access site infection with the need to surgical intervention
Time frame: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death (whichever comes first), at the timepoint of surgical intervention up to 30 days.
Time to extubation
Time to extubation in hours
Time frame: At 30 days post revascularization
Time to ambulation
Time to ambulation in hours
Time frame: At 30 days post revascularization
Cumulative incidence of escalation to VA-ECMO, LVAD or heart transplant
Cumulative incidence of escalation to VA-ECMO, LVAD or heart transplant
Time frame: At 30 days and 180 days post revascularization
Major adverse kidney events (MAKE)
Death (from any cause) or new requirement for renal replacement therapy (RRT) (e.g., dialysis) or persistent renal dysfunction (PRD) (defined as a worsening of kidney function denoted by ≥ 25% decline in the estimated glomerular filtration rate (eGFR) from baseline)
Time frame: At 30 days and 180 days post revascularization
Plan to share: No — Due to data protection regulations and study contracts
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 30 months is below that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital of Cologne